TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034.
Tumor necrosis factors are a group of cytokines that are secreted by macrophages and may induce cell death of certain tumor cell lines, which leads to inflammation. TNF inhibitors are the drug that stops inflammation. They are mainly indicated for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, anklyosing Spondilitis They are also called TNF blockers. Currently only five TNF are approved which include humira (adalimumab), remicade (infliximab), cimzia (Certolizumab pegol), enbrel (etanercept), and simponi (golimumab). Humira is the king and bestselling drug of the century due to high clinical efficacy and is approved for multiple indications. Entry of biosimilar in the market, major patent expiry of blockbuster drug, and strong ongoing clinical pipeline of biosimilar has boosted the growth of TNF biosimilar market. Moreover, the rising incidence and prevalence of rheumatic disease and switching trends from traditional treatment to biologic therapy have increased the growth of the market. However, stringent government regulation and entry of other promising therapy in the market hamper the growth of the market.
The global TNF biosimilar market is segmented by drug, distribution channel, and geography. On the basis of drug the global market is further sub segmented into Adalimumab biosimilars (Amjevita, Yusimry, Cyltezo, Exemptia, and others (including products approved in developing countries and pipeline products)), Infliximab biosimilars (Avsola (infliximab-axxq), Flixabi (SB2), Inflectra (infliximab-dyyb), Zessly, and others), Certolizumab biosimilars, Etanercept biosimilars, (Benepali, Nepexto, Eticovo, Erelzi, and others), Golimumab biosimilars. Infliximab biosimilar segment followed by etanercept biosimilar segment is expected to hold significant share of the market due to early patent expiry and entry of biosimilars like erie Etanercept-szzs and Infliximab-dyyb into the major market like Europe and United States. On the basis of distribution channel the global market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. Hospital pharmacy segment dominates the global market followed by retail pharmacy and online pharmacy. Online pharmacy segment is expected to grow at high CAGR due to the increase in number internet user and ease of use.
At regional level, the global TNF biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by North America is major contributor for the global TNF biosimilar market. This is because strong ongoing clinical pipeline of biosimilars, increasing research and drug development activities, presence of major players, and increase in demand for biosimilars propels the growth of the market in the region. Asia Pacific is the third promising revenue contributor which is expected to grow at a rapid pace in upcoming year. Countries such as Japan, India, and China are major contributors to this market. Emerging and colossal population base countries such as China and India offer tremendous market opportunities for the TNF biosimilar market. Entry of biosimilar will increase patient affordability and accessibility which in turn increase in consumption of TNF in low-income countries.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 16.5% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug, By Distribution Channel |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Alvotech, Amgen, Amgen Inc., AYUMI Pharmaceutica, Biocon, Biogen, Biosimilar Collaborations Ireland Limited, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Cordavis Ltd., Epirus Biopharmaceuticals, Fresenius Kabi, Glenmark Pharmaceuticals, Hanwha Chemical, Hetero, Innovent Biologics, Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics), LG Chem, Lupin, Mabpharm, Merck, Mylan, Nichi-Iko Pharmaceutical, Organon & Co., Pfizer, Ranbaxy Laboratories (now Sun Pharma), Samsung Bioepis, Sandoz, Shanghai CP Guojian Pharmaceutical, Sorrento Therapeutics (partner), Stada Arzneimittel AG, Sunshine Guojian Pharmaceutical, Synermore, Teva, Torrent Pharmaceuticals, YL Biologics, Zydus Cadila, and other prominent players. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global TNF Biosimilars Market Outlook, by Drug
Global TNF Biosimilars Market Outlook, by Application
Global TNF Biosimilars Market Outlook, by Distribution Channel
Global TNF Biosimilars Market Outlook By Region
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.